Beyond Next Ventures
VC Fund
Tokyo, Japan
Beyond Next Ventures is a Tokyo-based venture capital firm that invests in medical and life science fields.
- Total investments:
- 149
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $68M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Beyond Next Ventures invests in
Stages Beyond Next Ventures invests in
Countries Beyond Next Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Hashizume Katsuya
|
|||
Kengo Ueha
|
|||
Shota Sagiyama
|
|||
Tsuyoshi Ito
|
|||
1 more contact available
Investment Focus
Industry
- Health Care 25 (17%)
- Medical 20 (13%)
- Biotechnology 17 (11%)
- Manufacturing 10 (7%)
- Nursing and Residential Care 10 (7%)
Stage
- Seed 45 (30%)
- Series A 30 (20%)
- Funding Round 23 (15%)
- Series B 13 (9%)
- Venture - Series Unknown 4 (3%)
Country
- Japan 65 (44%)
- India 9 (6%)
- United States 3 (2%)
- Hong Kong 2 (1%)
- Singapore 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hashizume Katsuya
Partner
|
Partner | Total investments: 8 | Find email | |
|
Kengo Ueha
Managing Director & General Partner
|
Managing Director & General Partner | Total investments: 0 | Find email | |
|
Shota Sagiyama
Head of HR Support & Executive Officer
|
Head of HR Support & Executive Officer | Total investments: 0 | Find email | |
|
Tsuyoshi Ito
Managing Partner & CEO
|
Managing Partner & CEO | Total investments: 19 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Scohia Pharma
|
Scohia Pharma is a biotech venture that will have both substantial research and development resources and be nimble enough to make decisions quickly, will strive to improve patient quality of life by providing patients and healthcare professionals with new therapeutic medications for renal, metabolic. | $442.5M / May 28, 2026 | |
Atom
|
Atom is a humanoid robot built platform. Its bipedal, dual-armed robots are designed not just as industrial tools but as collaborators that expand human capability. By combining advanced Physical AI—environmental perception, judgment, and action planning—with robust robotic hardware, Atom is creating adaptive agents capable of working acrossdiverse settings to augment or, where appropriate, replace human labor. The company positions these robots as a next step in societal evolution: a new class of machines that learn and behave in human-like ways to advance productivity, safety, and quality of life. | $18.8M / Seed / May 27, 2026 | |
Anaut
|
Anaut specializes in software development utilizing artificial intelligence for surgical support in surgical medicine. | Series B / Mar 01, 2026 | |
Aqua Theon
|
Aqua Theon is a biotech startup focused on seaweed-based innovations for food, wellness, and sustainability. The company develops edible products, biodegradable packaging, and medical capsules using proprietary seaweed processing technology. | $13M / Seed / Feb 27, 2026 | |
FullDepth
|
FullDepth is a company that creates marine drones to aid with underwater monitoring. The company's drones work in tandem with marine navigation technology, which monitors and captures aquatic life, communicates data to connected devices, and provides infiltration information that can be freely used with a cloud service, allowing customers towitness and study marine life for educational and recreational purposes.FullDepth is a company that creates marine drones to aid with underwater monitoring. The company's drones work in tandem with marine navigation technology, which monitors and captures aquatic life, communicates data to connected devices, and provides infiltration information that can be freely used with a cloud service, allowing customers to witness and study marine life for educational and recreational purposes. | $60.6M / Series D / Dec 09, 2025 | |
GramEye
|
GramEye is a developer of medical equipment that uses robotics and deep learning to automate gram staining. The company operates under the assumption that the growth of germs that are resistant to antibiotics is a natural occurrence brought on by the usage of these medications. It aspires to a world in which antibiotics are correctly prescribed inall medical contexts. GramEye analyzes medical data, create web services, and create mobile applications as a health sciences company. | $3.6M / Series B / Nov 21, 2025 | |
|
GramEye
|
GramEye is a developer of medical equipment that uses robotics and deep learning to automate gram staining. The company operates under the assumption that the growth of germs that are resistant to antibiotics is a natural occurrence brought on by the usage of these medications. It aspires to a world in which antibiotics are correctly prescribed inall medical contexts. GramEye analyzes medical data, create web services, and create mobile applications as a health sciences company. | $3.6M / Series B / Nov 21, 2025 | |
Umami United
|
UMAMI UNITED is Japanese inspired plant-based food brand.We are willing to enrich the alt-protein market with unique and innovative Japanese ingredients. Our products are packed full of UMAMI flavor which provides an intense and savory flavor. The first product is UMAMI Egg which is made from Konjac powder as main ingredient. | $20.3M / Seed / Oct 27, 2025 | |
FinalLayer
|
FinalLayer is developing AI agents for creative processes. The FinalLayer LinkedIn post agent chooses the appropriate video clips to include in your post, writes posts in your own voice, and follows topics on your behalf. | Oct 23, 2025 | |
Neautech
|
Neautech is an application that offers online beauty experiences as well as influences beauty products. | $7.4M / Series B / Oct 17, 2025 | |
| See all 149 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Beyond Next Ventures invest in?
Beyond Next Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 149 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Beyond Next Ventures?
Public channels for Beyond Next Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Beyond Next Ventures?
The team at Beyond Next Ventures includes Hashizume Katsuya (Partner), Kengo Ueha (Managing Director & General Partner) and Shota Sagiyama (Head of HR Support & Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
